SMSPHARMA vs WINDLAS: Stock Comparison

SMS Pharmaceuticals Limited vs Windlas Biotech Ltd

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

SMS Pharmaceuticals Limited is the larger company by market capitalisation. SMS Pharmaceuticals Limited shows a higher ROE and a higher net margin, while Windlas Biotech Ltd shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of SMS Pharmaceuticals Limited and Windlas Biotech Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, SMSPHARMA is more favourable on 5 of 13 scored metrics and WINDLAS on 8These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SMSPHARMA is the larger company
₹3,560 Cr vs ₹1,754 Cr
P/E Ratio
WINDLAS has a lower P/E
26.93x vs 34.95x
P/B Ratio
WINDLAS has a lower P/B
3.08x vs 4.54x
EPS
WINDLAS has higher earnings per share
₹31.5 vs ₹11.17
Dividend Yield
WINDLAS has a higher dividend yield
0.73% vs 0.1%
Revenue Growth (TTM YoY)
WINDLAS has faster revenue growth
17.7% vs -4.1%
EPS Growth (TTM YoY)
SMSPHARMA has faster EPS growth
49.2% vs -2.6%
Qtr Sales Growth
WINDLAS has stronger quarterly sales growth
17.7% vs -4.13%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricSMSPHARMAWINDLAS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricSMSPHARMAWINDLAS
Live Price₹380.75₹849
Day Change-2.85%-0.99%
Volume1.03 L13,436
52-Week High₹447.8₹1,097.9
52-Week Low₹207.99₹697.4
Distance from 52W High-14.97%-22.67%

Valuation

MetricSMSPHARMAWINDLAS
Market Cap₹3,560 Cr₹1,754 Cr
P/E Ratio34.95x26.93x
P/B Ratio4.54x3.08x
EPS₹11.17₹31.5
Book Value₹81.83₹275
Dividend Yield0.1%0.73%

Growth

MetricSMSPHARMAWINDLAS
Revenue Growth (TTM YoY)-4.1%17.7%
EPS Growth (TTM YoY)49.2%-2.6%
Qtr Sales Growth-4.13%17.7%
Qtr Profit Growth61%-1.78%

Profitability & Leverage

MetricSMSPHARMAWINDLAS
ROE14.3%12.2%
ROCE13.3%15.9%
Net Margin11.5%7.35%
Operating Margin19.3%11.6%
Debt to Equity0.46x0.06x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricSMSPHARMAWINDLAS
Promoter Holding68.07%63.31% 1.41 pp
FII Holding0.65% 0.34 pp2.04% 1.44 pp
DII Holding2.83% 0.19 pp9.84% 1.97 pp
Public Holding28.45% 0.15 pp24.8% 0.9 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SMS Pharmaceuticals Limited and Windlas Biotech Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.